[go: up one dir, main page]

DK3013964T3 - Sammensætninger til indføring af rna i celler - Google Patents

Sammensætninger til indføring af rna i celler Download PDF

Info

Publication number
DK3013964T3
DK3013964T3 DK14742474.1T DK14742474T DK3013964T3 DK 3013964 T3 DK3013964 T3 DK 3013964T3 DK 14742474 T DK14742474 T DK 14742474T DK 3013964 T3 DK3013964 T3 DK 3013964T3
Authority
DK
Denmark
Prior art keywords
compositions
cells
introducing rna
rna
introducing
Prior art date
Application number
DK14742474.1T
Other languages
English (en)
Inventor
Christian Koch
Christian Dohmen
Christian Plank
Carsten Rudolph
Original Assignee
Ethris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethris Gmbh filed Critical Ethris Gmbh
Application granted granted Critical
Publication of DK3013964T3 publication Critical patent/DK3013964T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/30Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/0206Polyalkylene(poly)amines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/0206Polyalkylene(poly)amines
    • C08G73/0213Preparatory process
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
DK14742474.1T 2013-06-28 2014-06-27 Sammensætninger til indføring af rna i celler DK3013964T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13174390 2013-06-28
EP13181380 2013-08-22
PCT/EP2014/063756 WO2014207231A1 (en) 2013-06-28 2014-06-27 Compositions for introducing rna into cells

Publications (1)

Publication Number Publication Date
DK3013964T3 true DK3013964T3 (da) 2020-06-15

Family

ID=51224914

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14742474.1T DK3013964T3 (da) 2013-06-28 2014-06-27 Sammensætninger til indføring af rna i celler

Country Status (13)

Country Link
US (2) US12064484B2 (da)
EP (1) EP3013964B1 (da)
JP (1) JP6609246B2 (da)
KR (1) KR102285326B1 (da)
CN (1) CN105579584B (da)
AU (1) AU2014300980B2 (da)
BR (1) BR112015032225B1 (da)
CA (1) CA2916800C (da)
DK (1) DK3013964T3 (da)
EA (1) EA036400B1 (da)
ES (1) ES2810298T3 (da)
WO (1) WO2014207231A1 (da)
ZA (1) ZA201509111B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663360T3 (es) 2011-06-08 2018-04-12 Translate Bio, Inc. Lípidos escindibles
KR20160121584A (ko) * 2014-02-26 2016-10-19 에트리스 게엠베하 Rna의 위장 투여용 조성물
WO2015173824A1 (en) 2014-05-14 2015-11-19 Alex Levitzki Management And Holdings Ltd Improved polyethyleneimine polyethyleneglycol vectors
JP2017534649A (ja) * 2014-11-10 2017-11-24 エスリス ゲーエムベーハーethris GmbH Bmpをコードするrnaの送達による骨形成誘導
ES2861001T3 (es) 2015-06-30 2021-10-05 Ethris Gmbh Polirribonucleótidos que codifican la familia del casete de unión a ATP y formulaciones de los mismos
PH12018501168B1 (en) * 2015-12-01 2024-05-17 Spark Therapeutics Inc Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
MX2018013919A (es) * 2016-06-09 2019-04-15 Curevac Ag Portadores hibridos para cargas de acido nucleico.
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
WO2018127382A1 (en) 2017-01-03 2018-07-12 Ethris Gmbh Ornithine transcarbamylase coding polyribonucleotides and formulations thereof
WO2019204451A1 (en) * 2018-04-17 2019-10-24 Carnegie Mellon University Enhanced lipid nanoparticle drug delivery using a negatively charged polymer
BR112020021054A2 (pt) 2018-04-25 2021-02-17 Ethris Gmbh composição, processo para a preparação de uma composição, e, composições sólida e para uso
JP7607340B2 (ja) 2019-02-14 2024-12-27 エスリス ゲーエムベーハー 繊毛病の治療
CN111249476B (zh) * 2020-02-19 2023-09-26 深圳厚存纳米药业有限公司 泊洛沙姆和/或泊洛沙胺与脂质组合中性复合物纳米粒
EP4553084A3 (en) 2020-11-04 2025-11-26 Ethris GmbH Use of ifn-lambda mrna for treating viral infections
WO2022180213A1 (en) 2021-02-26 2022-09-01 Ethris Gmbh Formulations for aerosol formation and aerosols for the delivery of nucleic acid
US20240277616A1 (en) * 2021-05-07 2024-08-22 Carnegie Mellon University Lipid Nanoparticle-Mediated mRNA Delivery to the Pancreas
CN113876639B (zh) * 2021-11-12 2023-08-22 湖北省麦诗特生物科技有限公司 一种含有提高皮肤弹性脂质体的面霜组合物及其制备方法
JP2025529925A (ja) 2022-08-26 2025-09-09 エスリス ゲーエムベーハー 安定な脂質またはリピドイドナノ粒子懸濁液
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
WO2024121160A1 (en) 2022-12-05 2024-06-13 Ethris Gmbh Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency
EP4676525A2 (en) 2023-03-03 2026-01-14 DIOSynVax Ltd Coronavirus vaccines
WO2024240962A1 (en) 2023-05-25 2024-11-28 Ethris Gmbh Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
WO2025036956A1 (en) 2023-08-14 2025-02-20 Ethris Gmbh Non-systemic mrna administration
WO2025045767A1 (en) 2023-08-25 2025-03-06 Ethris Gmbh Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
TW202539697A (zh) 2023-11-15 2025-10-16 德商拜恩技術股份公司 冠狀病毒疫苗
GB202416789D0 (en) 2023-11-15 2025-01-01 BioNTech SE SARS-COV-2 immunogenic compositions
WO2025255152A1 (en) * 2024-06-05 2025-12-11 Oregon State University Polymeric compounds and lipid compositions made using the same
WO2026017917A1 (en) 2024-07-19 2026-01-22 Ethris Gmbh Rnas with reduced ribosomal frameshift expression products

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
AU5345999A (en) 1998-08-14 2000-03-06 Valentis, Inc. Protected one-vial formulation for nucleic acid molecules, methods of making thesame by in-line mixing, and related products and methods
NZ512244A (en) * 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
CA2377207C (en) 1999-06-25 2013-01-08 Christian Plank Combinations for introducing nucleic acids into cells
WO2002000870A2 (en) 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
EP1409647A4 (en) 2001-04-30 2009-09-09 Yissum Res Dev Co COMPOSITE SKELETONS AND METHODS OF USE THEREOF FOR GENERATING COMPLEX TISSUE GRAFT
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
CA2590820A1 (en) * 2004-12-17 2006-06-22 Nitto Denko Corporation Immobilized degradable cationic polymer for transfecting eukaryotic cells
US7829657B2 (en) 2005-02-10 2010-11-09 The University Of Tokyo Polycationically charged polymer and the use of the same as a carrier for nucleic acid
US20060235459A1 (en) 2005-04-19 2006-10-19 Das Gladwin S Balloon catheters and methods for manufacture
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US20120021042A1 (en) * 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
AU2006325054B2 (en) 2005-12-15 2013-05-02 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
AU2009311667B2 (en) * 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2010065660A2 (en) * 2008-12-02 2010-06-10 University Of Utah Research Foundation Biodegradable polydisulfide amines for gene delivery
CN102695525B (zh) 2009-07-31 2016-01-20 埃泽瑞斯公司 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
US9168230B2 (en) 2011-05-26 2015-10-27 University Of South Carolina Tetrary gene delivery system for gene therapy and methods of its use
DE102011114986A1 (de) 2011-09-28 2013-03-28 Ethris Gmbh Sprühsystem
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
WO2014066811A1 (en) 2012-10-25 2014-05-01 The Johns Hopkins University Bioreducible poly (b-amino ester)s for sirna delivery
HRP20220717T1 (hr) * 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
CA2884870C (en) * 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof

Also Published As

Publication number Publication date
EP3013964A1 (en) 2016-05-04
CN105579584A (zh) 2016-05-11
CA2916800C (en) 2022-10-25
BR112015032225A2 (pt) 2017-07-25
EA036400B1 (ru) 2020-11-06
JP6609246B2 (ja) 2019-11-20
CN105579584B (zh) 2020-08-28
KR102285326B1 (ko) 2021-08-04
CA2916800A1 (en) 2014-12-31
BR112015032225B1 (pt) 2022-05-17
ES2810298T3 (es) 2021-03-08
AU2014300980A1 (en) 2016-01-07
EP3013964B1 (en) 2020-05-06
WO2014207231A1 (en) 2014-12-31
US12064484B2 (en) 2024-08-20
US20250041443A1 (en) 2025-02-06
KR20160040524A (ko) 2016-04-14
EA201600044A1 (ru) 2016-06-30
US20170021036A1 (en) 2017-01-26
AU2014300980B2 (en) 2020-03-05
ZA201509111B (en) 2021-03-31
JP2016524898A (ja) 2016-08-22

Similar Documents

Publication Publication Date Title
DK3013964T3 (da) Sammensætninger til indføring af rna i celler
DK2978419T3 (da) Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf
IL245573B (en) Cell
PL2884999T3 (pl) Sposób i kompozycje do immunoterapii komórkowej
EP3488847C0 (en) SEMIFLUORINATED ALKANE COMPOSITIONS
BR112015027279A8 (pt) métodos e composições para acentuar células t reguladoras cd4+
DK2953634T3 (da) Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
DK3079658T3 (da) Kammer til indkapsling af secernerende celler
DK3042411T3 (da) Metalunderstøttet fastoxidbrændselscelle
PL3017520T3 (pl) Zespół ogniw słonecznych
DK2941483T3 (da) Fremgangsmåde til at opnå immunstimulerende dendritriske celler
FI11677U1 (fi) Uusiutuva hiilivetykoostumus
DK2686434T3 (da) Fremgangsmåde til reduktion af viskositet i saccharificeringsproces
LT3702351T (lt) Kompozicijos, apimančios mek inhibitorių
DK3242903T3 (da) Sammensætninger til at indføre nukleinsyre i celler
DK2941484T3 (da) Fremgangsmåde til at opnå immunsuppressive dendritriske celler
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
EP3011599C0 (en) PHOTOVOLTAIC DEVICES
DK3394248T3 (da) Dendritisk cellesammensætning
EP3719852C0 (en) SOLAR CELL
FI11676U1 (fi) Uusiutuva hiilivetykoostumus
DK2970843T3 (da) Fremgangsmåder til frembringelse af cellebank med høj densitet
DK3003285T3 (en) Fast farmaceutisk dosisform til frigivelse af mindst to aktive farmaceutiske ingredienser i mundhulen
EP3066193C0 (en) CELL CULTURE PROCESS
KR102535561B9 (ko) 태양 전지를 이용한 구조물